List of Excipients in Branded Drug ARICEPT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ARICEPT	donepezil hydrochloride	54868-3952	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	ARICEPT	donepezil hydrochloride	54868-3952	HYDROXYPROPYL CELLULOSE
Physicians Total Care Inc	ARICEPT	donepezil hydrochloride	54868-3952	HYPROMELLOSES

ARICEPT Excipient Strategy and Commercial Opportunities for Donepezil Formulations

Last updated: August 23, 2026

Aricept is the brand name for donepezil hydrochloride, an oral acetylcholinesterase inhibitor approved for symptomatic treatment of Alzheimer’s disease. Its core U.S. patents and regulatory exclusivities have expired, leaving limited value in conventional generic tablets. The strongest commercial opportunities are in geriatric-friendly delivery systems, taste masking, dose flexibility, preservative-free liquids, adherence products, and differentiated donepezil combinations.

What formulations and excipients does Aricept use?

Aricept is marketed in conventional film-coated tablets and orally disintegrating tablets. The labeled strengths include 5 mg, 10 mg, and 23 mg tablets, with 5 mg and 10 mg orally disintegrating tablets. Aricept is administered once daily, usually at bedtime. [1]

Aricept presentation	Strengths	Principal excipient platform	Commercial function
Film-coated tablet	5 mg, 10 mg, 23 mg	Lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc and coating materials	Conventional low-cost oral dosage form
Orally disintegrating tablet	5 mg, 10 mg	Mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, aspartame and magnesium stearate	Rapid disintegration and administration without water
Generic immediate-release tablet	Usually 5 mg and 10 mg	Varies by manufacturer; commonly lactose or mannitol, cellulose-based fillers, starch, crospovidone or croscarmellose, and magnesium stearate	ANDA-based substitution for Aricept tablets
Generic orally disintegrating tablet	Usually 5 mg and 10 mg	Varies by manufacturer; commonly mannitol, microcrystalline cellulose, crospovidone or low-substituted hydroxypropyl cellulose, sweeteners and flavors	Adherence and swallowing differentiation
Donepezil oral solution or suspension	Product-specific	Water-based vehicle, buffer, sweetener, flavor, preservative or preservative-free system	Dose titration and dysphagia use

The Aricept orally disintegrating tablet uses mannitol as a water-soluble bulking agent and a cellulose-based disintegrant system. Aspartame supports palatability but creates a labeling issue for patients with phenylketonuria. [1] A successor product can replace aspartame with sucralose, acesulfame potassium, steviol glycosides or another suitable sweetener, subject to formulation performance and FDA review.

What excipient strategy is most attractive for donepezil?

The most commercially relevant strategy is to improve administration for older adults without changing donepezil exposure. The target population has high rates of dysphagia, cognitive impairment, caregiver dependence, polypharmacy and inconsistent medication administration.

1. Taste-masked orally disintegrating tablets

Donepezil has a bitter taste. An ODT that disintegrates rapidly but leaves a bitter residue may have poor real-world acceptance, particularly when caregivers administer medication directly.

A differentiated ODT could combine:

• Mannitol or isomalt for mouthfeel and cooling sensation.
• Crospovidone or low-substituted hydroxypropyl cellulose for rapid disintegration.
• Ion-exchange resin complexation or polymeric coating for taste masking.
• Sucralose or acesulfame potassium instead of aspartame.
• Flavor systems designed for older adults, such as vanilla, mint or mild fruit profiles.
• Low-moisture packaging, including aluminum-aluminum blister packs.

The formulation objective is usually a short disintegration time, acceptable mechanical strength, low friability and limited bitterness during the initial residence period in the mouth. A taste-masked ODT may support a formulation patent if the claim recites a defined resin complex, coating composition, dissolution profile or sensory performance.

2. Sprinkle or soft-food dosage forms

A sprinkle formulation could target patients who cannot swallow tablets but can consume medication mixed with applesauce, pudding or another soft food. The product would need to maintain dose uniformity after transfer into food and avoid unacceptable bitterness.

Potential formats include:

• Coated multiparticulates.
• Mini-tablets.
• Taste-masked granules.
• Drug-loaded pellets.
• Sprinkle capsules.

The main technical risk is that coating or multiparticulate processing can alter dissolution and produce delayed or incomplete release. A sprinkle product also requires clear administration instructions and stability data after opening or mixing.

3. Oral liquid and unit-dose products

A ready-to-use oral solution or suspension could address patients with advanced dysphagia, feeding-tube use or difficulty handling solid dosage forms. The commercial value is higher in institutional, home-health and specialty-pharmacy channels than in routine retail substitution.

Key excipient decisions include:

Formulation issue	Strategic choice
Solubility	True solution if achievable; otherwise suspension or cosolvent system
Palatability	Sweetener, flavor and bitterness suppression
Microbial control	Preserved multidose bottle or preservative-free unit dose
Dose accuracy	Oral syringe-compatible packaging
Tube administration	Demonstrated compatibility with common enteral tubes
Stability	Protection from hydrolysis, oxidation, light and microbial growth
Caregiver use	Unit-dose packaging and clear storage instructions

A preservative-free, unit-dose product could command a higher price than a standard generic solution, but its market is narrower. The product must justify added packaging and manufacturing costs through improved adherence, reduced dosing errors or institutional procurement advantages.

4. 23 mg dose optimization

The 23 mg Aricept tablet was approved for moderate-to-severe Alzheimer’s disease after patients had received 10 mg daily for at least three months. The 23 mg strength is associated with greater gastrointestinal adverse events than the 10 mg strength and requires careful patient selection. [1]

This creates an opportunity for:

• Intermediate-strength titration, such as 15 mg or 20 mg.
• Modified-release delivery to reduce peak-related gastrointestinal effects.
• Multiparticulate dosing that can be titrated.
• Combination packaging for 10 mg-to-23 mg escalation.
• Lower-burden administration for caregivers.

A new strength or modified-release formulation would likely require a new regulatory strategy rather than a routine ANDA. Depending on the clinical and pharmacokinetic changes, a 505(b)(2) application could be more appropriate. The commercial opportunity depends on demonstrating a clinically meaningful benefit, not merely a different excipient profile.

What excipients protect the branded Aricept formulations?

The excipients themselves generally do not create meaningful exclusivity. Protection usually arises from a combination of:

• Specific excipient ratios.
• Particle or granule architecture.
• Taste-masking coatings.
• Disintegration and dissolution performance.
• Stability characteristics.
• Manufacturing process parameters.
• New dosage strengths or delivery systems.

The original Aricept tablet formulation relied on conventional pharmaceutical excipients. The ODT platform used conventional direct-compression or orally disintegrating-tablet materials. Those compositions do not provide a durable current barrier to generic entry.

An innovator or specialty-generic company seeking patent protection would need claims directed to a technical result, such as:

• A defined donepezil-resin complex with controlled release of drug in saliva.
• A specific coating that suppresses bitterness while preserving gastric dissolution.
• A low-moisture ODT with specified tensile strength and disintegration.
• A stable liquid formulation with a defined pH range and preservative-free shelf life.
• A multiparticulate formulation compatible with soft food or enteral administration.
• A dose-escalation kit with a defined administration sequence.

Broad claims covering donepezil plus routine fillers or sweeteners would face substantial validity and obviousness risks.

When did Aricept lose exclusivity and patent protection?

Aricept’s core U.S. regulatory and patent protection has expired. The product is no longer protected by a current period of new-drug exclusivity that blocks ordinary generic competition.

Milestone	Approximate timing	Commercial effect
Original FDA approval for Aricept tablets	1996	Established donepezil tablet product
Aricept ODT approval	2004	Added water-free administration option
Aricept 23 mg approval	2010	Expanded high-dose product segment
Core compound and formulation protection	Expired before or around the early 2010s, depending on patent and pediatric extension	Removed meaningful blocking protection
Generic donepezil tablet entry	2010	Accelerated price erosion for 5 mg and 10 mg tablets
Current market status	Generic-dominated	Commercial value shifts to formulation and channel differentiation

The Orange Book should be checked for the current listing status of any remaining patents associated with a specific Aricept or donepezil reference product. Historical Orange Book listings do not establish current enforceability, and patent expiration dates can differ by patent, pediatric extension and dosage form. [2]

What is the FDA regulatory status of Aricept and generic donepezil?

Aricept is an FDA-approved prescription drug. Generic donepezil tablets have been approved through the Abbreviated New Drug Application pathway. An ANDA applicant generally must show pharmaceutical equivalence and bioequivalence to the applicable reference product. [3]

A formulation that changes only inactive ingredients can remain within an ANDA pathway when the dosage form, strength, route, performance and labeling requirements remain acceptable. A product with a new delivery system, new indication, clinically meaningful pharmacokinetic difference or substantial formulation change may require a 505(b)(2) application.

ANDA opportunity

An ANDA is most suitable for:

• Conventional immediate-release tablets.
• Standard 5 mg and 10 mg strengths.
• ODTs that match the reference product’s performance.
• Low-cost products using commonly accepted excipients.

The competitive weakness is price. Conventional tablets have limited differentiation and are exposed to multiple generic suppliers.

505(b)(2) opportunity

A 505(b)(2) strategy is more suitable for:

• Oral solutions.
• Preservative-free unit-dose products.
• Sprinkle formulations.
• Modified-release or pulsatile-release products.
• New strengths.
• Products with a clinically supported tolerability or adherence advantage.

The pathway may reduce the need to repeat the full development program, but it does not eliminate the need for product-specific pharmacokinetic, safety, stability and, where relevant, clinical evidence.

Which companies are challenging Aricept, and what is the litigation status?

Donepezil has been challenged primarily through ordinary generic competition rather than an active branded patent litigation cycle. Multiple manufacturers have marketed generic donepezil tablets and orally disintegrating tablets. The competitive field includes large generic companies, specialty-generic suppliers and regional manufacturers.

Historical Paragraph IV activity occurred as generic companies sought approval before expiration of remaining listed patents. Those disputes were linked to the product’s original patent and later dosage-form protection. The principal commercial consequence was generic entry, not preservation of a long-term branded monopoly.

No biosimilar pathway applies. Donepezil is a small-molecule drug, so competitive products are generics, not biosimilars. Settlement agreements, where historically used, must be reviewed in the relevant court docket and FDA patent certification record rather than inferred from current market presence. The absence of current brand exclusivity makes a new Paragraph IV campaign against Aricept commercially limited unless a specific, unexpired Orange Book-listed patent remains relevant.

How strong is the patent estate for a new donepezil excipient product?

A new donepezil formulation can have moderate patent potential but a weak composition-of-matter position. The strongest claims would focus on measurable formulation attributes and a manufacturing process that is difficult to design around.

Claim area	Relative strength	Key risk
Donepezil plus conventional filler	Low	Routine and obvious formulation combination
ODT with standard mannitol and cellulose excipients	Low to moderate	Extensive prior art
Defined taste-masking complex	Moderate	Design-around and enablement challenges
Preservative-free liquid with stability data	Moderate	Narrow claim scope and process variability
Multiparticulate sprinkle product	Moderate	Prior art and bioequivalence complexity
Novel modified-release profile	Moderate to strong if clinically useful	Higher development cost
Specialized manufacturing process	Moderate	Need for reproducible commercial-scale performance
Device-plus-formulation combination	Moderate	Potentially stronger commercial differentiation

A robust portfolio would combine composition claims, process claims, use claims where legally available, packaging claims and trade-secret protection for flavor and coating processes.

What commercial opportunities exist beyond generic Aricept tablets?

Geriatric adherence products

The most accessible opportunity is a palatable ODT with low handling burden. Packaging could include calendar blisters, caregiver-readable labeling and dose-escalation instructions. The product would compete on adherence and convenience rather than molecule access.

Institutional and long-term-care products

Long-term-care facilities value accurate administration, reduced swallowing burden and simplified medication rounds. Unit-dose oral liquids, ODTs and sprinkle products may have better institutional economics than standard bottles, particularly when they reduce crushed-tablet preparation.

Enteral feeding-tube administration

A validated liquid or dispersible formulation compatible with feeding tubes could address a defined clinical need. The product would require data on tube adsorption, clogging, recovery of dose and compatibility with common nutrition products.

Fixed-dose combination products

Donepezil is already used in combination with memantine in the Namzaric product. A combination product can reduce pill burden, but its formulation and patent landscape are more complex than a standalone excipient reformulation. [4] Commercial development would need to account for existing combination-product patents, generic competition and the different titration requirements of donepezil and memantine.

International and emerging markets

Outside the United States, opportunities may exist for:

• Low-cost ODTs.
• Oral solutions.
• Local-language caregiver packaging.
• Aluminum blister systems for hot and humid climates.
• Products designed for limited access to clean water.
• Hospital and institutional unit-dose packaging.

Geographic freedom to operate must be assessed separately because national patent terms, regulatory requirements and reference-product rules differ.

How does Aricept compare with competing Alzheimer’s drugs?

Aricept competes with other symptomatic therapies and newer disease-modifying products, but its excipient opportunity is different because generic donepezil is inexpensive and widely available.

Product category	Primary differentiation	Excipient opportunity
Donepezil tablets	Low price and established use	Limited
Donepezil ODT	Swallowing convenience	Moderate
Donepezil liquid or sprinkle	Dysphagia and caregiver administration	Moderate to high
Memantine	NMDA receptor antagonist; moderate-to-severe disease	Similar liquid and adherence opportunities
Donepezil/memantine combination	Reduced pill burden	Combination formulation and titration
Monoclonal antibody therapies	Disease-modifying treatment for selected patients	Limited relevance to donepezil excipients
Rivastigmine patch	Transdermal delivery	Donepezil transdermal systems would require major development

Rivastigmine’s patch demonstrates the value of nonoral delivery in dementia, but a donepezil patch would face substantial formulation, pharmacokinetic and clinical-development requirements. It would not be a simple excipient substitution.

What generic launch risks exist for a new Aricept formulation?

The main risks are commercial rather than patent-based.

1. Generic tablets establish a low price benchmark.
2. Caregivers and prescribers may not switch from familiar tablets without a clear administration benefit.
3. ODT products can be difficult to manufacture at scale with adequate hardness and fast disintegration.
4. Taste masking can reduce dissolution or increase tablet size.
5. Liquid products carry packaging, microbial-control and stability costs.
6. The 23 mg dose has a narrower tolerability profile.
7. Medicare and Medicaid reimbursement may not support a large premium for convenience.
8. Formulation claims can be designed around by changing sweeteners, disintegrants, coatings or particle architecture.

The best launch profile is a product with a defined target population, a demonstrable administration problem and a reimbursement or institutional purchasing rationale.

Key Takeaways

• Aricept contains donepezil hydrochloride and is available in conventional tablets, 23 mg tablets and 5 mg/10 mg orally disintegrating tablets.
• Its branded exclusivity has expired, and standard generic tablets offer limited commercial differentiation.
• The most attractive excipient strategies involve taste-masked ODTs, sprinkle formulations, oral liquids, preservative-free unit doses and enteral-tube compatibility.
• Conventional excipient combinations have weak patent prospects because mannitol, cellulose derivatives, starches, lactose and magnesium stearate are well established.
• Stronger patents would require a defined technical effect, such as bitterness suppression, stability, dissolution control or improved administration.
• ANDA development fits conventional tablets and reference-matched ODTs. 505(b)(2) development is more suitable for new liquids, strengths, modified release and clinically differentiated delivery systems.
• Donepezil has generic competition, not biosimilar competition.
• Commercial success depends on adherence, caregiver use, long-term-care procurement and reimbursement, not on protection of the active ingredient.

FAQs About Aricept Excipient and Formulation Opportunities

Can lactose-free generic donepezil be commercially differentiated?

Yes. A lactose-free tablet or ODT could address excipient preferences, intolerance concerns or institutional formulary requirements. The differentiation is commercially modest unless combined with better disintegration, taste masking or packaging.

Is an aspartame-free Aricept ODT feasible?

Yes. Aspartame can be replaced with other sweeteners, but the developer must preserve taste, tablet strength, moisture stability, dissolution and regulatory acceptability. [1]

Can donepezil be formulated as a transdermal patch?

Technically possible, but it would require substantial development to achieve controlled delivery, adequate skin permeation, acceptable adhesion and predictable exposure. It would likely require a 505(b)(2) application and clinical support.

Does an Aricept excipient change require a new clinical trial?

Not necessarily. A reference-matched generic may rely primarily on pharmaceutical equivalence and bioequivalence. A new delivery system, strength, route or clinically meaningful pharmacokinetic profile may require additional studies.

Are there active Orange Book patents blocking a new donepezil formulation?

Core Aricept protection has expired. Any proposed product still requires a current Orange Book review for the relevant reference product, dosage form and listed patent claims. Historical patents do not automatically create a present blocking right.

References

1. U.S. Food and Drug Administration. (2023). Aricept (donepezil hydrochloride) prescribing information. Eisai Inc.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.
4. U.S. Food and Drug Administration. (2023). Namzaric (memantine hydrochloride and donepezil hydrochloride) prescribing information. Allergan USA, Inc.